Clinical Trials Logo

Lenvatinib clinical trials

View clinical trials related to Lenvatinib.

Filter by:

NCT ID: NCT04911959 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

Start date: July 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

single-center clinical trial studies have verified the safety and effectiveness of transcatheter arterial chemoembolization (TACE) combined with lenvatinib in preventing postoperative recurrence of microvascular invasion (MVI) positive HCC patients. Explore a new clinical first-line treatment plan for patients with liver cancer microvascular invasion after surgery.

NCT ID: NCT04791176 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC

Start date: April 12, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label study performed at our hospital, patients with progression hepatocellular carcinoma (HCC) met inclusion criteria will be enrolled. Patients received oral lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients<60kg ) before local radiotherapy 8 weeks, large lesions were treated with IMRT for 40-60gy / 20-30f. Combined therapy will be taken until unacceptable treatment-related toxicities occurred or disease progression.

NCT ID: NCT04669496 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Start date: January 20, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

A randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative recurrence-free survival. In this study, we aim to compare the prognosis in intrahepatic cholangiocarcinoma between Toripalimab combined with leventinib and GEMOX neoadjuvant treatment and the current clinical surgical treatment (traditional group).